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Kathryn B. Garber1,*Another Potential Benefit of Antioxidants
Several groups have reported a high frequency of mito-
chondrial DNA (mtDNA) mutations in tumors, but the
signiﬁcance of these mutations to cancer development
and progression is not fully understood. Ishikawa et al. re-
port evidence that these mutations are important, not for
tumor development, but for the development ofmetastatic
potential. They comparedmouse lung carcinoma cell lines,
one of which had high metastatic potential (A11) and one
of which had low metastatic potential (P29). The highly
metastatic A11 cells exhibited reduced activity of the mito-
chondrial respiratory complex I, and complete replace-
ment of the P29 mitochondria with A11 mitochondria
transferred both the increased metastatic potential and
decreased complex I activity to P29 cells. Similar results
were obtained for another set of mouse cancer cell lines
and a set of human cancer cell lines. Perhaps key to the
metastasis-promoting character of A11mtDNA is its associ-
ation with increased production of reactive oxygen species
(ROS) and subsequent changes in gene expression. These
effects, including the increased potential for metastasis in
a mouse model, could all be reversed if cells were treated
with the ROS scavenger N-acetylcysteine. Of note, the anti-
apoptotic gene MCL-1 was upregulated when A11 mtDNA
was present, but the metastatic potential of these cells was
suppressed if siRNA was used to downregulate expression
of this gene. Not only do these results give us a greater
understanding of the role of mtDNA in cancer, but they
also suggest that ROS scavengers are of interest in therapies
for controlling tumor metastasis.
Ishikawa et al. (2008). Science Express March 3. 10.1126/
science.1156906.
New Avenues for Cystic Fibrosis Research
How is cystic ﬁbrosis like a lysosomal storage disorder? It
appears that, similar to lysosomal storage disorders, cystic
ﬁbrosis is associated with an enzymatic deﬁciency that
leads to build-up of a substrate that is normally degraded
in lysosomes. Teichgraber et al. argue that reductions in
the activity of certain lysosomal enzymes, namely acid
sphingomyelinase (Asm) and—to a greater extent—acid
ceramidase, are central to the pathogenic process in cystic
ﬁbrosis. Whereas Asm results in production of ceramide byThe Amcleavage of sphingomyelin, acid ceramidase degrades it to
sphingosine. In mice deﬁcient for CFTR, alkalinization of
lysosomes alters the relative activity of these enzymes,
resulting in higher levels of ceramide in the respiratory ep-
ithelium. Similar increases in ceramide were found in the
nasal respiratory epithelium, the respiratory epithelium of
the lung, and in submucosal glands of people with cystic
ﬁbrosis. The role of increased ceramide in the lung destruc-
tion that devastates people with cystic ﬁbrosis is probably
at least two-fold: The ceramide leads to increased inﬂam-
mation in the absence of infection, and it also promotes
cell death in the respiratory epithelium. When the respira-
tory epithelial cells die, their DNA is deposited on the
mucosal surface, which promotes adherence of Pseudomo-
nas aeruginosa, the major pathogen that infects people
with cystic ﬁbrosis. Perhaps most exciting from a medical
perspective, all of these observations can be reversed by
genetic or pharmacologic reductions in Asm activity, sug-
gesting that ceramide plays a large role in the pathogenesis
of cystic ﬁbrosis. The drug used in these studies, amytripty-
line, is an inhibitor of Asm activity and is already approved
for use in humans as an antidepressant. Provided these
results are validated, ceramide might become a key target
for management of cystic ﬁbrosis.
Teichgraber et al. (2008). Nature Medicine 14, 382–391.
10.1038/nm1748.
If I Were a Geneticist .
If you’ve ever discussed your job with people at a cocktail
party, I’m sure you’re aware that the general public has
some misconceptions about genetics research. Perhaps
it’s not surprising when cover stories such as ‘‘Fat Gene’’
and ‘‘Know Your Genetic Risks and How to Fight Them’’
appear on popular news magazines. As part of the Gen-
EdNet project of ASHG, Shaw et al. decided to quantify
genetic misconceptions among high-school students in
the United States through use of essays submitted to the
GenEdNet website as part of a contest. Of the 500 essays
that were systematically reviewed in their study, over half
(55.6%) contained at least one obvious misconception
about genetics. When Shaw et al. grouped the misconcep-
tions into related topics, they found that themost frequent
category included statements in which the capabi-
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overestimates included the thought that perfect, designer
babies will be possible in the near future. Perhapsmore sur-
prisingly, of the essays that had amisconception about pat-
terns of inheritance, 80% inaccurately described a basic
Mendelian principle, and terms such as DNA, gene, and
chromosome were often used imprecisely. This work sug-
gests that improvements need to be made in teaching ge-
netics, even the basics, to our young people. Because these
students are going to be the future consumers of genetic in-
formation, wemight all begin to think about our role in the
education of the public, both at school age and beyond.
Shaw et al. (2008). Genetics 178, 1157–1168. 10.1534/
genetics.107.084194.
When to Have HAART
Although it has huge beneﬁt in the HIV-positive popula-
tion, highly active antiretroviral therapy (HAART) is also
expensive and has the potential for long-term toxicity.
Thus, to reduce its negative effects, current guidelines for
the prescription of HAARTsuggest that it not be given until
the CD4þ T cell count drops below a level of 350 CD4þ T
cells/mm3. However, there is variability in the recovery
of T cell counts in response to therapy, so a one-size-ﬁts-
all recommendation on the timing of HAART might not
be the best way to go. Ahuja et al. report genetic underpin-
nings for some of the variability in response to HAART.
They found that variation in the genes for CCR5, themajor
HIV coreceptor, and its ligand CCL3L1 inﬂuence the
reconstitution of CD4þ T cell counts in people on HAART.
Speciﬁcally, there are CCL3L1-CCR5 genetic risk groups
that predicted impaired CD4þ T cell recovery with HAART
when it was initiated at <350 CD4þ T cellsmm3. They sug-1026 The American Journal of Human Genetics 82, 1025–1026, Maygest that perhaps individuals with a genetically deter-
mined poor response to HAART might beneﬁt if they are
identiﬁed and given HAART early so that they can mini-
mize the time they spend with risky CD4þ T cell counts.
Ahuja et al. (2008). Nature Medicine 14, 413–420.
10.1038/nm1741.
Rare Variants under Pressure
It is becoming evident that common genetic variants will
be able to explain some of the phenotypic variation in
complex traits, as proposed in the common disease-com-
mon variant hypothesis. But genome-wide association
studies for some common traits, such as hypertension,
haven’t produced the same level of exciting results. Ji
et al. wondered whether rare genetic variants might be
the key to traits such as hypertension. They ﬁgured that
carriers of rare mutations that cause severe recessive
blood-pressure disorders might have different blood pres-
sures than noncarriers. Indeed, in the Framingham Heart
Study offspring cohort, they identiﬁed proven or inferred
loss-of-function mutations in three genes—SLC12A3,
SLC12A1, and KCNJ1—that produced clinically signiﬁcant
reductions in blood pressure. By age 60, mutation carriers
have a striking 59% reduction in risk of hypertension
when they are compared with noncarriers, an effect that
is similar in size to that of current antihypertensive agents.
Although these variants don’t explain the majority of
hypertension in a general population, they do suggest
that perhaps multiple rare variants will together play a
big role in the variability of certain complex traits.
Ji et al. (2008). Nature Genetics, published online April 6,
2008, in press. 10/1038.ng.118.2008
